Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients

25 Feb 2009

Abstract excerpt

BACKGROUND: A significant portion of ovarian cancer (OC) cases is caused by germ-line mutations in BRCA1 or BRCA2 genes. BRCA testing is cheap in populations with founder effect and therefore recommended for all patients with OC diagnosis. Recurrent mutations constitute the vast majority of BRCA defects in Russia, however their impact in OC morbidity has not been yet systematically studied. Furthermore, Russian...

Topics

Join the communities discussing this publication.

BRCA gene mutations in cancer
Ovarian cancer diagnosis and treatment
PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 19338682
DOI: 10.1186/1897-4287-7-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patientsPMID 19338682Read ↗

Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients.Semantic proximity Read ↗

Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.Semantic proximity Read ↗

Frequency of BRCA1 and BRCA2 causative founder variants in ovarian cancer patients in South-East PolandSemantic proximity Read ↗

High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer.Semantic proximity Read ↗

Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer PatientsSemantic proximity Read ↗

[Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips].Semantic proximity Read ↗

Hereditary ovarian cancer in Poland.Semantic proximity Read ↗

Targeted next-generation sequencing of 21 candidate genes in hereditary ovarian cancer patients from the Republic of Bashkortostan.Semantic proximity Read ↗

Recurrent Mutations in BRCA1, BRCA2, RAD51C, PALB2 and CHEK2 in Polish Patients with Ovarian CancerSemantic proximity Read ↗

A high proportion of founder BRCA1 mutations in Polish breast cancer families.Semantic proximity Read ↗

Genetic testing in Poland and Ukraine: should comprehensive germline testing of BRCA1 and BRCA2 be recommended for women with breast and ovarian cancer?Semantic proximity Read ↗

High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.